AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12382950 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (1500 pulses ESWT at 0.12 mJ/mm2)
Number of subjects: 75
Study 12382950 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 75
Study 11369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 176
Study 11369909 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus environmental changes
Number of subjects: 176
Study 11369909 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 176
Study 9272102 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement at 0.024 mg/kg per day
Number of subjects: 42
Study 9272102 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement at 0.012 mg/kg per day
Number of subjects: 42
Study 9272102 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement (both doses)
Number of subjects: 42
Study 9272102 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients continuing GH therapy
Number of subjects: 42
Study 8257527 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analog SMS 201-995 (SMS) at doses ranging from 0.8-2.2 micrograms/kg sc
Number of subjects: 37
Study 8257527 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analog SMS 201-995 (SMS) at standard doses of 1 microgram/kg sc
Number of subjects: 37
Study 3001518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal alpha 2-interferon
Number of subjects: 120
Study 31587317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraorifice barrier group (glass-ionomer cement barrier + GIC base + composite resin restoration)
Number of subjects: 120
Study 31587317 — intervention group
Group type: EXPERIMENTAL
Intervention: Base group (2-mm-thick GIC base + composite resin restoration)
Number of subjects: 120
Study 31587317 — intervention group
Group type: COMPARATOR
Intervention: Control group (pulp chamber filled with composite resin only)
Number of subjects: 120
Study 29415851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (two lectures on healthy nutrition followed by weight monitoring over 6 weeks)
Number of subjects: 89
Study 29415851 — intervention group
Group type: COMPARATOR
Intervention: Control (weighed at baseline, post-lectures and at study closure)
Number of subjects: 89
Study 29415851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 27531732 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted ADL programme delivered by an occupational therapist (in addition to usual care)
Number of subjects: 30
Study 27531732 — intervention group
Group type: COMPARATOR
Intervention: Usual care (6 weeks of homecare reablement delivered by social care workers)
Number of subjects: 30
Study 25940353 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based scheme for diagnosis and treatment of schistosomiasis mansoni
Number of subjects: 0
Study 25940353 — intervention group
Group type: COMPARATOR
Intervention: Community-based scheme for diagnosis and treatment of schistosomiasis mansoni
Number of subjects: 0
Study 25940353 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of positives for Schistosoma mansoni with praziquantel
Number of subjects: 0
Study 25940353 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of positives for soil-transmitted helminthes (STH) with mebendazole
Number of subjects: 0
Study 25940353 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment of positives for S. mansoni
Number of subjects: 0
Study 23080288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Number of subjects: 0
Study 23080288 — intervention group
Group type: COMPARATOR
Intervention: Hib plus MCC vaccine
Number of subjects: 0
Study 23080288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 21134613 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase (0.58 mg)
Number of subjects: 66
Study 21134613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18197912 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-8 measurement in pleural fluid at a cutoff value of 1000 pg/mL
Number of subjects: 100
Study 18197912 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP measurement in pleural fluid at a cutoff value of 80 mg/L
Number of subjects: 100
Study 18197912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural fluid tests (including pH, glucose, LDH, IL-8, and CRP)
Number of subjects: 100
Study 18197912 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of pleural fluid parameters
Number of subjects: 100
Study 17313855 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF 100 microg/kg (single subcutaneous injection on day 3)
Number of subjects: 104
Study 17313855 — intervention group
Group type: COMPARATOR
Intervention: rhG-CSF 5 microg x kg(‐1) x d(‐1) (daily subcutaneous injection starting on day 3 for 14 days)
Number of subjects: 104
Study 14728105 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg t.i.d.)
Number of subjects: 70
Study 14728105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombotic risk factors
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased Lp(a) level (>30 mg/dL)
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: FV G1691A mutation
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: PT G20210A variant
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR TT677 genotype
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C type I deficiency
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired IgG ACAs
Number of subjects: 273
Study 11022077 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional triggering factors (asphyxia, septicemia, maternal diabetes, renal venous thrombosis)
Number of subjects: 273
Study 8828247 — intervention group
Group type: COMPARATOR
Intervention: medication only, no contingencies
Number of subjects: 353
Study 8828247 — intervention group
Group type: COMPARATOR
Intervention: standard counseling, no contingencies
Number of subjects: 353
Study 8828247 — intervention group
Group type: EXPERIMENTAL
Intervention: enhanced services, contingency contracting
Number of subjects: 353
Study 8828247 — intervention group
Group type: COMPARATOR
Intervention: non-contingent conditions
Number of subjects: 353
Study 1441947 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-loaded PMMA (20 mg of growth hormone)
Number of subjects: 30
Study 1441947 — intervention group
Group type: COMPARATOR
Intervention: Cemented or cementless hip replacement without added growth hormone (Control)
Number of subjects: 30
Study 30269002 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 127
Study 30269002 — intervention group
Group type: EXPERIMENTAL
Intervention: Script-Driven Imagery (SDI)
Number of subjects: 127
Study 30269002 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 127
Study 26755219 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 20
Study 26755219 — intervention group
Group type: EXPERIMENTAL
Intervention: BioAggregate
Number of subjects: 20
Study 24433126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairing steamed broccoli with cheese pizza for lunch
Number of subjects: 57
Study 24433126 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing visual appeal of raw cucumber as semicircles with chive and olive garnish
Number of subjects: 57
Study 24433126 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing visual appeal of raw cucumber arranged in a visually appealing manner (in the shape of a caterpillar)
Number of subjects: 57
Study 23161338 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycling) for 3 months
Number of subjects: 0
Study 23161338 — intervention group
Group type: COMPARATOR
Intervention: Table football (control)
Number of subjects: 0
Study 19406399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy (n = 101)
Number of subjects: 215
Study 19406399 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic hysteroscopy and myoma biopsy (n = 103)
Number of subjects: 215
Study 19463299 — intervention group
Group type: EXPERIMENTAL
Intervention: TriActiv System (Kensey‐Nash Corp.)
Number of subjects: 631
Study 19463299 — intervention group
Group type: COMPARATOR
Intervention: Guardwire (Medtronic)
Number of subjects: 631
Study 19463299 — intervention group
Group type: COMPARATOR
Intervention: Filterwire (Boston Scientific)
Number of subjects: 631
Study 15936468 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (doses equivalent to gliclazide 40 mg = glimepiride 1 mg, glibenclamide 2.5 mg = glimepiride 2 mg)
Number of subjects: 172
Study 15936468 — intervention group
Group type: COMPARATOR
Intervention: Conventional SU (gliclazide or glibenclamide, no change in treatment)
Number of subjects: 172
Study 15936468 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 172
Study 12921927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 150
Study 12921927 — intervention group
Group type: COMPARATOR
Intervention: Urologic Surgeons
Number of subjects: 150
Study 10802396 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 57
Study 8874326 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha 2a (9 million IU) subcutaneously three times weekly with 5‐FU (750 mg/m2/d) by continuous intravenous infusion on days 1 to 5 and then weekly IV bolus at the same dose
Number of subjects: 245
Study 8874326 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU alone at the same dose schedule
Number of subjects: 245
Study 1642918 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid preload 20 ml kg‐1 over 10 min
Number of subjects: 20
Study 1642918 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid preload 20 ml kg‐1 over 20 min
Number of subjects: 20
Study 6541254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheehy Collar Button tube
Number of subjects: 939
Study 31407320 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-14 scheme with rituximab
Number of subjects: 0
Study 31407320 — intervention group
Group type: COMPARATOR
Intervention: CHOP-14 scheme without rituximab
Number of subjects: 0
Study 29241615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (medical supply kits, cupboard for storage, tracking sheet, one-day training session)
Number of subjects: 218277
Study 27374220 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBV) placement
Number of subjects: 30
Study 27374220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 24650832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTI)
Number of subjects: 56
Study 24650832 — intervention group
Group type: COMPARATOR
Intervention: Behavioral placebo treatment (BPT)
Number of subjects: 56
Study 22584558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by a 2 mg/kg/h infusion until the end of the surgical procedure)
Number of subjects: 70
Study 22584558 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70
Study 21526667 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (B group)
Number of subjects: 40
Study 21526667 — intervention group
Group type: COMPARATOR
Intervention: Saline (S group, placebo group)
Number of subjects: 40
Study 16531614 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg)
Number of subjects: 3749
Study 16531614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 (40 mg)
Number of subjects: 3749
Study 16531614 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg) + Vitamin B6 (40 mg)
Number of subjects: 3749
Study 16531614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3749
Study 14509561 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg as needed
Number of subjects: 362
Study 14509561 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 500 microg as needed
Number of subjects: 362
Study 10694782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter (30.7 g/d) consumed in the form of black chocolate
Number of subjects: 12
Study 10694782 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 12
Study 9380281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, single oral dose)
Number of subjects: 0
Study 9380281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride combined with ACTH
Number of subjects: 0
Study 8096475 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose infusion
Number of subjects: 164
Study 8096475 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 164
Study 8096475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxytocin infusion)
Number of subjects: 164
Study 2864051 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg once daily
Number of subjects: 10
Study 31916036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sage-containing mouthwash
Number of subjects: 48
Study 31916036 — intervention group
Group type: COMPARATOR
Intervention: Water/alcohol-based placebo
Number of subjects: 48
Study 31073188 — intervention group
Group type: EXPERIMENTAL
Intervention: APO-assisted training program
Number of subjects: 10
Study 31073188 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional self-paced overground walking)
Number of subjects: 10
Study 28105902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive porcine small intestine submucosa (SIS; Oasis Ultra)
Number of subjects: 0
Study 25583029 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based simulation for 3 hours
Number of subjects: 67
Study 24162940 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 889
Study 24162940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 889
Study 24162940 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and paracetamol
Number of subjects: 889
Study 21865791 — intervention group
Group type: EXPERIMENTAL
Intervention: PMMA-CHDF
Number of subjects: 43
Study 21865791 — intervention group
Group type: COMPARATOR
Intervention: PAN-CHDF
Number of subjects: 43
Study 19466669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg taken 1 hour prior to sexual activity)
Number of subjects: 19
Study 19466669 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (sertraline, paroxetine)
Number of subjects: 19
Study 19466669 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (fluoxetine)
Number of subjects: 19
Study 17297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy
Number of subjects: 82
Study 17297553 — intervention group
Group type: COMPARATOR
Intervention: Topical nitroglycerin
Number of subjects: 82
Study 17297553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 15199624 — intervention group
Group type: EXPERIMENTAL
Intervention: SQNYCH combined with chemotherapy
Number of subjects: 114
Study 15199624 — intervention group
Group type: COMPARATOR
Intervention: Western medicine only
Number of subjects: 114
Study 12397048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 41
Study 12397048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9523211 — intervention group
Group type: EXPERIMENTAL
Intervention: Inheritance of shared epitope (SE) alleles
Number of subjects: 180
Study 9523211 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype model of SE alleles
Number of subjects: 180
Study 9523211 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 SE copies
Number of subjects: 180
Study 7535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0
Study 7535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 7535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 0
Study 7535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Other cytokines (M-CSF, IL-3, PIXY321, SCF, IL-1, IL-6, IL-11)
Number of subjects: 0
Study 2692962 — intervention group
Group type: COMPARATOR
Intervention: HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg)
Number of subjects: 2320
Study 336002 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP) in combination with Benzerazide
Number of subjects: 30
Study 336002 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30
Study 336002 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP)
Number of subjects: 30
Study 30989165 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Interactive Working Memory Training (VIMT), n = 33, 45 min sessions 3 times per week for a total of 36 sessions
Number of subjects: 66
Study 30989165 — intervention group
Group type: COMPARATOR
Intervention: Active control group, n = 33, 45 min sessions 3 times per week for a total of 36 sessions
Number of subjects: 66
Study 27784634 — intervention group
Group type: EXPERIMENTAL
Intervention: Creamy soundtrack
Number of subjects: 0
Study 27784634 — intervention group
Group type: COMPARATOR
Intervention: Rough soundtrack
Number of subjects: 0
Study 26247351 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-capsules containing menthol/PCL
Number of subjects: 10
Study 22975664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel plus cilostazol (intensification group, n = 72)
Number of subjects: 146
Study 22975664 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (control group, n = 74)
Number of subjects: 146
Study 22975664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel plus cilostazol (intensification group)
Number of subjects: 146
Study 22975664 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (control group)
Number of subjects: 146
Study 22975664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 21906885 — intervention group
Group type: EXPERIMENTAL
Intervention: High stress group
Number of subjects: 59
Study 21906885 — intervention group
Group type: COMPARATOR
Intervention: Low stress group
Number of subjects: 59
Study 19558562 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA (1.5 g for 1 year)
Number of subjects: 39
Study 19558562 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli Nissle (EcN)
Number of subjects: 39
Study 16122956 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg) given orally for 4 days prior to oesophageal acid infusion
Number of subjects: 0
Study 16122956 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Parecoxib (40 mg) given 120 min after oesophageal acid infusion
Number of subjects: 0
Study 16122956 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo given orally for 4 days prior to oesophageal acid infusion
Number of subjects: 0
Study 16122956 — intervention group
Group type: COMPARATOR
Intervention: Saline given IV 120 min after oesophageal acid infusion
Number of subjects: 0
Study 15513550 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily nasal spray with physiological saline
Number of subjects: 108
Study 11176172 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal monocytes incubated with septic serum
Number of subjects: 20
Study 11176172 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal monocytes incubated with septic serum and anti-IL-10 antibodies
Number of subjects: 20
Study 11176172 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal monocytes incubated with anti-TGF-beta antibodies
Number of subjects: 20
Study 11176172 — intervention group
Group type: EXPERIMENTAL
Intervention: Septic monocytes stimulated with endotoxin
Number of subjects: 20
Study 11176172 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls stimulated with endotoxin
Number of subjects: 20
Study 9472123 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic monitoring in children with ADHD
Number of subjects: 12
Study 9472123 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (N=12)
Number of subjects: 12
Study 9472123 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective parental reports
Number of subjects: 12
Study 9316690 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (FZ) 20 mg
Number of subjects: 10
Study 9316690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (CZ) 150 mg
Number of subjects: 10
Study 9316690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2898422 — intervention group
Group type: EXPERIMENTAL
Intervention: olsalazine 500 mg bd
Number of subjects: 164
Study 2898422 — intervention group
Group type: COMPARATOR
Intervention: sulphasalazine 1 g bd
Number of subjects: 164
Study 30780126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and metformin therapy
Number of subjects: 42
Study 30780126 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 42
Study 28922158 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based individually‐tailored and adaptive Computerized Cognitive Training (CCT)
Number of subjects: 45
Study 28922158 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (AC)
Number of subjects: 45
Study 23737342 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with targeted arterial infusion of verapamil
Number of subjects: 40
Study 23737342 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with targeted arterial infusion of verapamil in patients with liver metastases
Number of subjects: 40
Study 23737342 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of patients
Number of subjects: 40
Study 22153362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nap (45 min NREM sleep)
Number of subjects: 55